Bpifrance’s Adverum Biotechnologies ADVM Stock Holding History

Bpifrance’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-82,826	Closed	-$4.34M	–	8
2019 Q1	$4.34M	Hold	82,826	–	–	0.49%	7
2018 Q4	$2.61M	Buy	+82,826	New	+$3.37M	0.33%	9

Other funds holding ADVM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Bpifrance's ADVM Position: Q2 2019 in Review

Bpifrance sold out of Adverum Biotechnologies (ADVM) in Q2 2019, closing a stake of 82,826 shares — an estimated $4.34M sold.

Bpifrance first reported a position in ADVM in Q4 2018 and held it in 2 quarters. The position peaked at $4.34M in Q1 2019. 94 funds tracked by Wall St. Rank hold ADVM as of Q2 2019.

Bpifrance reported no remaining Adverum Biotechnologies position as of Q2 2019 after selling out during the quarter.
Bpifrance sold 82,826 Adverum Biotechnologies shares in Q2 2019, an estimated $4.34M.
Bpifrance first reported a position in Adverum Biotechnologies in Q4 2018 and held it in 2 quarters.
Bpifrance's Adverum Biotechnologies position peaked at $4.34M in Q1 2019.
94 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2019.

Based on Bpifrance's 13F filing for Q2 2019, filed 14 Nov 2019.